標靶藥物、生物製劑和免疫療法在眼科疾病之成效

The Impact of Target Therapy, Biologics and Immunotherapy on Ocular Disorders

黃千慈(Chian-Tzu Huang) ； 吳若玄(Jo-Hsuan Wu) ； 陳偉勵(Wei-Li Chen)

《台灣醫學》 25卷4期 (2021/07) Pp. 489-492

https://doi.org/10.6320/FJM.202107_25(4).0006

摘要

「標靶藥物」、「生物製劑」和「免疫治療」等新興療法為目前藥理界的新主流，不僅在全身許多疾病上蓬勃地發展，也影響了眼科病患的治療思維。本篇文章對這類藥物的藥理特色做簡要的說明，並簡介這些藥物在眼科疾病的應用，或是可能因為其他科別的應用上，導致病患產生眼科疾病。

關鍵字

標靶藥物 ； 生物製劑 ； 免疫療法 ； 眼科 ； 合併症

並列摘要

＂Target therapy＂, ＂biologics＂ and ＂immunotherapy＂ are currently the new mainstreams in the field of clinical pharmacology. They are wildly used in the treatment of ocular diseases. However, systemic use of these drugs may also lead to ocular complications. In this article, the basic concept of these drugs and their role in ophthalmic filed was discussed.

並列關鍵字

target therapy ； biologics ； immunotherapy ； ocular ； complication

參考文獻

Chu HS, Hu FR, Yang CM, et al. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition. Cornea 2011;30:60-6.

Chu HS, Chen TC, Hu FR, et al. Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab. Cornea 2013;32:1446-53.

Lin CT, Hu FR, Kuo KT, et al. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Invest Ophthalmol Vis Sci 2010;51:6277-85.

Chen WL, Chen YM, Chu HS, et al. Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization. PLOS ONE 2014;9: e94205.

Goel V, Raina S, Chandragouda D, et al. Trichomegaly of eyelashes after treatment with erlotinib in carcinoma pancreas. Int J Trichology 2014;6:23-4.